SEC Form 4 · accession 0001144204-15-011312
Eloxx Pharmaceuticals, Inc. · ELOX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harlan Waksal
Director
Period of report
Feb 19, 2015
Accepted (ET)
Feb 23, 2015 · 12:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001035354
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock OptionF1 | $0.54 | Feb 19, 2015 | A | 26,552 | A | Feb 19, 2015 | Feb 19, 2025 | Common Stock | 26,552 | 136,353 | D |
Explanation of responses
- F1Such options were granted in lieu of cash compensation under the Company's independent director compensation plan and are immediately exercisable.